Holds 3 valid CEPs for potassium clavulanate, filing since 2025. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 6 markets.
EDQM certificate database
EDQM certificate database
Holds 3 valid CEPs for potassium clavulanate, filing since 2025. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 6 markets.
Holds 3 valid CEPs for potassium clavulanate, filing since 2025. Its 2023 FDA inspection closed as VAI, and its GMP is recognised in 5 markets.
Holds 2 valid CEPs for potassium clavulanate, filing since 2024. Its GMP is recognised in 16 markets.
Holds 7 valid CEPs for potassium clavulanate, filing since 2020. Its GMP is recognised in 13 markets.
Registered with SFDA (Saudi Arabia) for potassium clavulanate. Its 2024 FDA inspection closed as NAI.
Holds 2 valid CEPs for potassium clavulanate, filing since 2025.
Registered with SFDA (Saudi Arabia) for potassium clavulanate. Its 2025 FDA inspection closed as VAI.
Holds 4 valid CEPs for potassium clavulanate, filing since 2019. Its 2023 FDA inspection closed as OAI, and its GMP is recognised in 3 markets.
Registered with SFDA (Saudi Arabia) for potassium clavulanate.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for freeFixed-dose combinations containing potassium clavulanate. Each page leads with the verified API makers of every component.